Nicola J. Curtin - Publications, H-index & Citations

Back

Nicola J. Curtin

newcastle university - uk

72H-index

421Paper Count

2.3WCitation Count

Published Papers 122

Publication Date

Oxidative stress and PARP activation in the lungs is an early event in COVID-19 pneumonia

Free Radical Biology and Medicine

IF8.2

2025-06-11

OAAI

Péter Juhász; Péter Bohus; Adrienn Sipos; Nicola Curtin; Gábor Méhes; Péter Bai

Save

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2024-11-12

PREAI

Drew, Yvette; Zenke, Frank T.; Curtin, Nicola J.

Save

The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2024-08-27

OAAI

Papp, Henrietta; Toth, Emese; Bovari-Biri, Judit; Banfai, Krisztina; Juhasz, Peter; Mahdi, Mohamed; Russo, Lilian Cristina; Bajusz, David; Sipos, Adrienn; Petri, Laszlo; Szalai, Tibor Viktor; Kemeny, Agnes; Madai, Monika; Kuczmog, Anett; Batta, Gyula; Mozner, Orsolya; Vasko, Dorottya; Hirsch, Edit; Bohus, Peter; Mehes, Gabor; Tozser, Jozsef; Curtin, Nicola J.; Helyes, Zsuzsanna; Toth, Attila; Hoch, Nicolas C.; Jakab, Ferenc; Keseru, Gyorgy M.; Pongracz, Judit E.; Bai, Peter

Save

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

BRITISH JOURNAL OF CANCER

IF6.8

2024-08-19

OAAI

Johnson, N.; Bentley, J.; Wang, L-Z; Newell, D. R.; Robson, C. N.; Shapiro, G. I.; Curtin, N. J.

Save

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

BRITISH JOURNAL OF CANCER

IF6.8

2024-07-04

OAAI

Smith, Hannah L.; Willmore, Elaine; Prendergast, Lisa; Curtin, Nicola J.

Save

Targeting the DNA damage response for cancer therapy

BIOCHEMICAL SOCIETY TRANSACTIONS

IF4.3

2023-01-06

OAAI

Curtin, Nicola J.

Save

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

CELLS

IF5.2

2022-08-01

OAAI

Bradbury, Alice; Zenke, Frank T.; Curtin, Nicola J.; Drew, Yvette

Save

Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations

JOURNAL OF PATHOLOGY CLINICAL RESEARCH

IF3.7

2021-10-17

OAAI

Ward, Tim H.; Gilbert, Duncan C.; Higginbotham, George; Morris, Chris M.; Speirs, Valerie; Curtin, Nicola J.

Save

Evaluation of MDM2-p53 antagonists, nutlin-3 and RG7388, combined with the PARPi rucaparib in primary cultures of ovarian cancer

ANNALS OF ONCOLOGY

IF65.4

2020-10-01

OAAI

Zanjirband, M.; Gentles, L.; Curtin, N. J.; O'Donnell, R. L.; Lunec, J.

Save

Poly(ADP-ribose) polymerase inhibition: past, present and future

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2020-09-03

342

PREAI

Curtin, Nicola J.; Szabo, Csaba

Save

Preclinical investigation of ATR inhibition alone and in combination with PARP inhibition in high risk neuroblastoma

CANCER RESEARCH

IF16.6

2020-08-15

PREAI

Southgate, Harriet E.; Chen, Lindi; Curtin, Nicola J.; Tweddle, Deborah A.

Save

Investigating synergy between CHK1 and PARP inhibitors in BRCA2 mutant and restored cells

CANCER RESEARCH

IF16.6

2020-08-15

PREAI

Smith, Hannah L.; Prendergast, Lisa; Curtin, Nicola J.

Save

Investigating determinants of sensitivity to ATR inhibition, as predictive biomarkers to single agent ATR inhibitor, VE-821, in ovarian cancer

CANCER RESEARCH

IF16.6

2020-08-15

PREAI

Bradbury, Alice Mary; Zenke, Frank T.; Drew, Yvette; Curtin, Nicola J.

Save

Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2020-07-05

OAAI

Curtin, Nicola; Banyai, Krisztian; Thaventhiran, James; Le Quesne, John; Helyes, Zsuzsanna; Bai, Peter

Save

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

FRONTIERS IN ONCOLOGY

IF3.3

2020-04-03

OAAI

Southgate, Harriet E. D.; Chen, Lindi; Curtin, Nicola J.; Tweddle, Deborah A.

Save

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

PHARMACOLOGY & THERAPEUTICS

IF12.5

2020-03-01

117

PREAI

Bradbury, Alice; Hall, Sally; Curtin, Nicola; Drew, Yvette

Save

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

NATURE REVIEWS CLINICAL ONCOLOGY

IF82.2

2019-10-03

PREAI

Curtin, Nicola J.; Drew, Yvette; Sharma-Saha, Sweta

Save

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

BIOCHEMICAL PHARMACOLOGY

IF5.6

2019-09-01

PREAI

Mukhopadhyay, Asima; Drew, Yvette; Matheson, Elizabeth; Salehan, Mo; Gentles, Lucy; Pachter, Jonathan A.; Curtin, Nicola J.

Save

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

BLOOD ADVANCES

IF7.1

2018-05-22

OAAI

Fordham, Sarah E.; Blair, Helen J.; Elstob, Claire J.; Plummer, Ruth; Drew, Yvette; Curtin, Nicola J.; Heidenreich, Olaf; Pal, Deepali; Jamieson, David; Park, Catherine; Pollard, John; Fields, Scott; Milne, Paul; Jackson, Graham H.; Marr, Helen J.; Menne, Tobias; Jones, Gail L.; Allan, James M.

Save

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

CANCER DISCOVERY

IF33.3

2017-06-01

337

OAAI

de Bono, Johann; Ramanathan, Ramesh K.; Mina, Lida; Chugh, Rashmi; Glaspy, John; Rafii, Saeed; Kaye, Stan; Sachdev, Jasgit; Heymach, John; Smith, David C.; Henshaw, Joshua W.; Herriott, Ashleigh; Patterson, Miranda; Curtin, Nicola J.; Byers, Lauren Averett; Wainberg, Zev A.

Save

Research Directions